Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

NCT04975256 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT04975256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 28, 2021
Completion date
November 15, 2022
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, malignant neoplasm of colon, malignant neoplasm of lung, malignant neoplastic disease, metastatic cancer